Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331273

Institution ID

3331273

Institution full name and acronym

Pfizer

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

12- and 18-Month Outcomes and Long- Term Survival of Tofacitinib in Ulcerative Colitis
A Descriptive Retrospective Database Study to Evaluate Serious Clinical Manifestations and Outcomes among SARS-CoV-2 Diagnosed Patients with RA, PsA or UC treated with systemic therapies: A Post Approval Safety Study of Tofacitinib in the Context of the COVID-19 Pandemic
A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data (B7451085)
A french AMBispective, multisite, non-interventional Real-life effectiveness and safety of ELranatanab for the treatment of patients with relapse or refractory multiple myelomA (RRMM) - (AMbreLA)
A Long-Term, Observational Study within the Corrona Inflammatory Bowel Disease (IBD) Registry to Characterize the Safety of Tofacitinib in Patients with Ulcerative Colitis in the Post-Approval Setting
A Longitudinal, Retrospective, Multi-centre Observational Study to Evaluate Effectiveness, Persistence, Treatment Patterns and Safety of Australian Patients Receiving Early Access to Tofacitinib
A multicenter evaluation of the treatment persistence of advanced therapies (Biological disease-modifying agents and Targeted synthetic Disease Modifying Anti-Rheumatic Drugs) in the treatment of rheumatoid arthritis (RA): A Real World Evidence (RWE) study from India
A national, multi-centre, longitudinal observational study evaluating the efficacy and safety under real-life conditions of use of TALZENNA® (talazoparib) in patients with somatic or germline BRCA mutated HER2 negative, locally advanced or metastatic breast cancer (Vital Study)
A network meta-analysis of real-world studies comparing tofacitinib with other advanced therapies in the treatment of moderate-to-severe ulcerative colitis
A non comparative , multi centre observational study: Isavuconazole (Cresemba) in Invasive Mould Infections (Invasive Aspergillosis, Invasive Mucormycosis) in India
A Non-Interventional Post-Approval Safety Study of Pfizer-BioNTech COVID-19 Vaccine in the United States
A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU
A Non-Interventional Post-Authorization Safety Study of Pfizer-BioNTech Bivalent COVID-19 Vaccine in the United States (US)
A Non-Interventional Study of Bosutinib in Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)
A population based cohort study to monitor the safety and effectiveness of sirolimus in patients with sporadic lymphangioleiomyomatosis (S-LAM)
A Population-based Study of the Safety of Gabapentin Use During Pregnancy
A POST AUTHORIZATION SAFETY SURVEILLANCE REGISTRY IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A IN USUAL CARE SETTINGS
A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK
A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK
A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) in the European Union Using Secondary Data Sources
A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) Using an Administrative Healthcare Database in France
A Post-Authorization Safety Study of Atrial Fibrillation Following Respiratory Syncytial Virus Vaccine (ABRYSVOTM) Among Older Adults in the Veterans Affairs Health System (C3671037)
A Post-Authorization Safety Study to Evaluate the Safety of Abrocitinib Exposure During Pregnancy in United States Healthcare Databases
A Post-Marketing Near Real-Time Safety Surveillance of Respiratory Syncytial Virus Vaccine for Guillain-Barre Syndrome (GBS) among Older Adults in the United States
A Post-Marketing Safety Study using a Pregnancy Registry to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy (C3671041)
A Pregnancy Registry Study to Evaluate the Safety of PENBRAYA™ Meningococcal Vaccine Exposure During Pregnancy
A Prospective Active Surveillance Study to Monitor Growth, Development, and Maturation Among Adolescents with Atopic Dermatitis Exposed to Abrocitinib
A Prospective Active Surveillance Study to Monitor the Real-World Safety of Ritlecitinib Among Adolescents with Alopecia Areata
A Prospective Observational Study within the Corrona International Registry to Evaluate Safety and Effectiveness of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in Japan among Patients Treated for Moderately to Severely Active Rheumatoid Arthritis
A Prospective, Observational Study to Assess the Long-Term Safety of Abrocitinib Treatment in Adult Patients with Moderate-to-Severe Atopic Dermatitis
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
A Rapid Surveillance and Cohort Post-Marketing Safety Study to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy in the United States (C3671027)
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
A Retrospective Database Study to Evaluate Rates of Influenza and Related Diagnoses between Patients Treated with Tofacitinib and Other Systemic Therapies within Cohorts of RA, PsA, and UC Patients: A Post-Authorization Safety Study of Tofacitinib
A standing cohort to understand the characteristics of patients with COVID-19 and contextualize the COVID-19 complication and safety events of interests using US OPTUM EHR data
Active Safety Surveillance of the Pfizer-BioNTech COVID-19 Vaccine in the United States Department of Defense Population Following Emergency Use Authorization
Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)
Administration of Elranatamab In the Real-World: Treatment Patterns, Healthcare Resource Utilization, Costs, Effectiveness, anD SafEty (ALTITUDE-2)
An Active Safety Surveillance Study to Estimate Incidence Rates of Safety Events of Interest among Patients Treated with Tofacitinib for Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry in the United States
An Active Surveillance Study to Monitor the Real-World Long-term Safety of Somatrogon Among Paediatric Patients in Europe
An Active Surveillance Study to Monitor the Safety of Abrocitinib Among Real-World Patients with Atopic Dermatitis (AD) in the European Union (EU)
An Active Surveillance, Post Authorization Safety Study (PASS) of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among Patients Treated with Tofacitinib for Moderately to Severely Active Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika Therapie (RABBIT) (Safety of tofacitinib in RABBIT)
An Active Surveillance, Post Authorization Safety Study (PASS) of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among Patients Treated with Tofacitinib for Moderately to Severely Active Rheumatoid Arthritis (RA) within the Swedish, Population based, Anti Rheumatic Treatment in Sweden (ARTIS) register. (Safety of tofacitinib in ARTIS)
An Active Surveillance, Post Authorization Safety Study (PASS) to Estimate Incidence Rates of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among all Patients Treated with Ruxience for Rheumatoid Arthritis (RA) within the British Society for Rheumatology Biologics Register Rheumatoid Arthritis (BSRBR RA)
An Active Surveillance, Post Authorization Safety Study (PASS) to Estimate Incidence Rates of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among all Patients Treated with Ruxience for Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika Therapie (RABBIT)
An Active Surveillance, Post-Authorisation Study to Characterize the Safety of Tofacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data from the Swedish Quality Register for Inflammatory Bowel Disease (SWIBREG)
An active surveillance, post-authorization safety study (PASS) of serious infection, malignancy, cardiovascular and other safety events of interest among patients treated with tofacitinib for moderately to severely active rheumatoid arthritis within the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis (BSRBR-RA) (Safety of tofacitinib in BSRBR-RA)
An active surveillance, post-authorization safety study of serious infection, malignancy, cardiovascular and other safety events of interest among patients treated with tofacitinib for moderately to severely active rheumatoid arthritis within the Spanish registry of adverse events of biological therapies and biosimilars in rheumatoid diseases (BIOBADASER) (Safety of tofacitinib in BIOBADASER)
An Active Surveillance, Post-Authorization Study to Assess Tofacitinib Utilization Patterns and to Characterize the Safety of Tofacitinib Use in Patients with Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data from a US Administrative Healthcare Claims Database
An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)
An evaluation of non-melanoma skin cancer and melanoma skin cancer rates among patients treated for moderately to severely active rheumatoid arthritis with Xeljanz® (tofacitinib citrate): A retrospective non-interventional database study of observational data embedded within Optimising Patient outcome in Australian RheumatoLogy - Quality Use of Medicines Initiative (OPAL-QUMI) (Skin cancer rates in OpaL - SOL study)
An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients
An International, Multicenter, Non-interventional Post-Authorization Safety Study to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated in Real-World Settings (MagnetisMM-16)
An International, Multicenter, Prospective Non-Interventional Study of Real-World Treatment Outcomes in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) treated with Talazoparib and Enzalutamide (TALENZA)
An observational study - Evaluation of efficacy and safety of Bosulif® under real life conditions of use (BOSEVAL)
An Observational Study of Xeljanz® (tofacitinib citrate) and Biologic Rheumatoid Arthritis Treatments to Characterize their General Treatment Patterns, Effectiveness and Safety in a Real-World Taiwanese Population
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)® (Voxelotor)
ARIA: Real-world utilization and outcomes with dacomitinib first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi center chart review (A7471067)
Assess Incidence and Prevalence of Brain Metastasis and Its impact on Clinical Outcomes among Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-small Cell Lung Cancer Patients Receiving ALK Inhibitors as First-Line Treatment in the United States (ALK+ mNSCLC)
Assessment of risk factors for Myocarditis in the United States (US) using Electronic Health Records and Claims data
Canadian Non-Interventional Study of Xeljanz in Rheumatoid Arthritis (CANTORAL)
Characterization and outcomes follow up of patients with rheumatoid arthritis initiating tofacitinib: A retrospective, observational PASS using the British Society of Rheumatology Biologics Register-Rheumatoid Arthritis (BSRBR-RA) A3921448
CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring
Clinical and Economic Outcomes and Treatment Patterns for Non-Valvular Atrial Fibrillation Patients Who Newly Initiated Oral Anticoagulants in the US Medicare Population
Comparative Effectiveness of Tofacitinib Versus Ustekinumab and Vedolizumab among Ulcerative Colitis Patients With Prior Anti- Tumor Necrosis Factor (TNF) Failure
Concept Elicitation Qualitative Study: Migraine Patient Experiences with Zavegepant
Demographics and treatment patterns of Turkish female HR (+) HER2 (-) mBC patients in real life setting
Describing Real-World Rimegepant Utilization Patterns and Understanding Perceptions of Migraine Treatment Optimization from the Perspectives of Patients
Effectiveness of the Additional Risk Minimization Measures in Conveying Safety Information to HCPs Dispensing, Administering or Prescribing Fosphenytoin
Evaluation of the effectiveness of additional risk minimisation measures (aRMM) materials for Xeljanz® (tofacitinib) in Europe via a survey of healthcare professionals (HCPs): A non interventional (NI) post authorisation safety study (PASS)
Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to reduce the risks of phototoxicity, squamous cell carcinoma (SCC) of the skin and hepatic toxicity in patients receiving voriconazole in Saudi Arabia
Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)
GO-First: Real-world treatment patterns and effectiveness outcomes associated with gemtuzumab ozogamicin in first-line Acute Myeloid Leukaemia
HERO-Together Boost: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine
HERO-Together: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine in US healthcare workers, their families, and their communities
Herpes zoster and other opportunistic infections in patients with inflammatory bowel disease in Norway – associations with immunosuppressive treatment (NOZOIBD)
Hospital Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated with Oral Anticoagulants in the U.S.
Impact of tafamidis in Colombian patients diagnosed with ATTR-CA in quality of life during two year of follow up
INOtuzumab Treatment Retrospective Analysis for Navigating tranSITion to CD19 CAR-T (INO-TRANSIT)
Machine learning prediction of anemia events before and after talazoparib dose modification using TALAPRO-2 phase 3 trial data
Major bleeding in patients with atrial fibrillation treated with apixaban versus warfarin in combination with amiodarone: the APIXAMIO study
Non-Interventional Postmarketing Safety Study to Evaluate the COMIRNATY 2024-2025 Formula (monovalent KP.2) in the United States
Non-Interventional Study - Use of lorlatinib in treatment-naïve adult patients with metastatic or locally advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) from India. (B7461047)
Non-Interventional Study to Review the Changes of Depression after First-Year of Tofacitinib Treatment in Rheumatoid Arthritis (XELJANZ®)
Non-interventional, real-world study of patients with early stage, human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC) receiving Trazimera (VESTA)
Observational Cohort Study of Zavegepant Safety in Pregnancy within a US Claims Database
Observational multicentric national longitudinal study evaluating Ibrance (palbociclib) in a real life setting conditions in patients 70 years old and older presenting a locally advanced or metastatic HR+/HER2- breast cancer (PalomAGE)
Observational Study of Effectiveness and Safety of Recombinant Zoster Vaccine (Shingrix)® in Moderately-to-Severely Active Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) Patients Treated with Tofacitinib (Xeljanz)® in Real- World Clinical Care Settings
Observational study to investigate safety and effectiveness of lorlatinib as first line treatment for ALK-gene rearranged unresectable advanced/recurrent NSCLC patients in Japan clinical setting
Observational, real-world study of INFLECTRA in patients with inflammatory bowel disease (IBD) in the United States and Canada (ONWARD)
Outcome of progression free survival in patients with advanced or metastatic, hormone receptor positive, HER2-negative breast cancer treated with palbociclib in combination with fulvestrant or letrozole
OZAVIE : Prospective observational study in patients treated with Zavicefta® (ceftazidime/avibactam) under real conditions of use
Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi country, non-interventional prospective cohort study among patients with human growth hormone (hGH) treatments under routine clinical care
Pfizer-BioNTech COVID-19 Vaccine Exposure during Pregnancy: A Non-Interventional Post-Approval Safety Study of Pregnancy and Infant Outcomes in the Organization of Teratology Information Specialists (OTIS)/MotherToBaby Pregnancy Registry
Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States
Post-Authorisation Active Safety Surveillance Program Among Patients Treated With Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Juvenile Psoriatic Arthritis (PsA) Using Nationwide Swedish Healthcare Registers
Post-Authorisation Active Safety Surveillance Program Among Patients Treated With Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Juvenile Psoriatic Arthritis (PsA) Within the German Biologics in Pediatric Rheumatology Registry (BiKeR) and Juvenile Arthritis Methotrexate/Biologics Long-term Observation (JuMBO) Registries (BiKeRJuMBO)
Post-Authorisation Active Safety Surveillance Program Among Patients Treated With Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Juvenile Psoriatic Arthritis (PsA) Within the United Kingdom (UK) Juvenile Idiopathic Arthritis (JIA) Biologics Register
Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe
Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries
Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran’s Affairs Health System Receiving Pfizer BioNTech Coronavirus Disease 2019 (COVID 19) Vaccine
Pregnancy and Infant Outcomes Following Exposure to PAXLOVID: A Post-Authorization Safety Study
Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer (MADELINE)
Prospective, Registry-Based Observational Cohort Study of Ritlecitinib Safety in Pregnancy
Prospective, Registry-Based Observational Cohort Study of Zavegepant Safety in Pregnancy
Real life effect of an epoietin alpha biosimilar Retacrit® on response to chemotherapy-induced anemia and fatigue at 16 weeks in elderly patients (ELDER)
REal Life Safety and effectiveness of tofAcitinib in comparison to TNF InhibitOrs using the French National Healthcare Database (RELATION)
Real world evidence of the usage of tofacitinib in Ulcerative Colitis patients in Lebanon
Real-world comparative effectiveness of tofacitinib, tumour necrosis factor inhibitors, and interleukin 17 inhibitors among patients with axial spondylarthritis and psoriatic arthritis
Real-world evaluation of effectiveness, persistence and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) Patients Treated With Glasdegib or Venetoclax in US Community Oncology Practices
Real-World Treatment Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as First Line Therapy in Post-Menopausal Women and Men With Metastatic Breast Cancer (P-REALITY 3)
Real-World Treatment Patterns and Clinical Outcomes of BRAF V600-Mutant Metastatic Melanoma Patients Treated at Academic Oncology Centers in the United States
Real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line (1L) axitinib + pembrolizumab therapy
Retrospective Assessment of Treatment Patterns and Outcomes Associated with Palbociclib in Combination With Letrozole in Postmenopausal Women With HR+/HER2– Advanced Breast Cancer
Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Retrospective observational study of the conditions of use, safety and efficacy of MYLOTARG® (Gemtuzumab Ozogamicin, GO) in the treatment of patients with newly diagnosed CD33-positive acute myeloid leukaemia (AML). (MYLobs)
Retrospective Post-Marketing Safety Surveillance Study of Tofacitinib in Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA)
Risk of Safety Events Among Patients with UC and PsA Treated with Tofacitinib and Other Advanced Treatments in the United States
Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
Safety of Paxlovid During Pregnancy
Tafamidis Pregnancy Surveillance Study
Tofacitinib Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project (OTIS PASS Tofacitinib)
Treatment patterns and clinical effectiveness outcomes of palbociclib in combination with aromatase inhibitor (AI) or fulvestrant in hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer patients: an observational study using Flatiron Electronic Health Record (EHR) database
Uveitis in chronic inflammatory conditions and ulcerative colitis-related pyoderma gangrenosum and axial spondylarthritis: an observational study of patients receiving advanced therapies in the United States
Viral SARS-CoV-2 rebounds in commercial pharmacy-based SARS-CoV-2 PCR testing